ClinicalTrials.Veeva

Menu

Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients

T

Tel Aviv Sourasky Medical Center

Status and phase

Unknown
Phase 2

Conditions

Obesity
Diabetes Mellitus, Type 2

Treatments

Drug: Fecal Microbiota Transplantation
Other: low fat high fiber diet
Other: high fat low fiber diet
Procedure: gastroscopy
Other: sham diet

Study type

Interventional

Funder types

Other

Identifiers

NCT02346669
TASMC-14-NM-447-CTIL

Details and patient eligibility

About

The incidence of obesity has dramatically increased during the last three decades, leading to a significant increase of obesity-related morbidity, including type 2 diabetes mellitus (T2DM) that is characterized by resistance of target tissues to insulin action. T2DM obese patients may be treated by medications or by bariatric surgery. Both alternatives have limitations due to incomplete resolution of the diseases, high cost or potential procedural related morbidity. An increasing body of evidence points to a role of the enteric microbiota in the pathogenesis of obesity-related insulin resistance. In addition to that, the gut microbiota is directly affected by the diet composition. Studies in T2DM mice carrying human gut germs, demonstrated special interactions between the gut microbiota and the host, creating a typical microbiota composition which changes significantly following diet change from a western diet, rich with sugar, to a vegetarian diet rich with fibers. This rapid alternations in the microbiota composition has also shown in humans, after changing from western to high fiber diet. A change in diet life style may lead to an improvement in T2DM symptoms such as decrease in visceral adipose tissue.

Full description

Study design:

30 Patients will undergo 2 FMT's from a lean donor and will be randomized into 3 types of diet groups:

  1. low fat high fiber diet (20% fat)
  2. no change in fat intake (sham diet)
  3. high fat low fiber diet (40-45% fat)

The treating physicians and the patients will be blinded for the diet arm. Before and after FMT, patients will be assessed after an overnight fast (and before taking medications) for weight, anthropometric measures, questionnaires (dietary, general health, antibiotic and probiotic exposure, oral diabetes medication quantity, and other drug exposure), blood and stool.

The investigators hypothesize that fecal microbial transplantation from a lean donor to T2DM obese patients, with the combination of low fat high fiber diet, will alter the gut microbiota composition to decrease insulin resistance through microbiota dependent metabolic and immunologic effects.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 30≤BMI

  • A diagnosis of T2DM (≥3 months) and one of the following:

    1. Fasting glucose level≥126mg/dL and/ or
    2. A stable dose of anti-diabetic drugs for ≥2 weeks and/or
    3. HbA1C≥6.5
  • Access to a smart phone supporting the research application for tracking food consumption.

Exclusion criteria

  • participation in other clinical trial
  • incapable of signing an informed consent
  • pregnancy or breast feeding
  • Antibiotic treatment within the prior 3 months or predicted antibiotic treatment
  • insulin medications
  • drugs or alcohol addiction
  • immune mediated diseases
  • type 1 diabetes and latent autoimmune diabetes of adults
  • systemic disease
  • ischemic heart disease
  • probiotics consumption
  • a new or unstable treatment with anti diabetic medications

Patients will also be excluded if:

  • treated by systemic antibiotic during the study
  • will not be compliant with the diet

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

30 participants in 3 patient groups

FMT from a lean donor+ high fat diet
Active Comparator group
Description:
Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy: 1. at time 0 2. after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study.
Treatment:
Other: high fat low fiber diet
Procedure: gastroscopy
Drug: Fecal Microbiota Transplantation
FMT from a lean donor+ sham diet
Sham Comparator group
Description:
Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy: 1. at time 0 2. after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study.
Treatment:
Procedure: gastroscopy
Other: sham diet
Drug: Fecal Microbiota Transplantation
FMT from lean donor+ low fat diet
Active Comparator group
Description:
Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy: 1. at time 0 2. after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study.
Treatment:
Other: low fat high fiber diet
Procedure: gastroscopy
Drug: Fecal Microbiota Transplantation

Trial contacts and locations

1

Loading...

Central trial contact

Nitsan Maharshak, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems